NCT00408681 · OUTCOME

Duration of Treatment With the Study Product

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant · Source last updated 2017-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: days
Interval / dispersion: Full Range
Time frame: Up to 6 months

What was measured

Number of days from beginning of orally administered lithium carbonate to the end of orally administered lithium carbonate

Groups in this outcome

Treated Patients

Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treated Patients	20

Reported measurements

Source class 1

Values in days · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Treated Patients	30.5	Not reported	7	172	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
7
upper Limit
172
value
30.5

denoms

counts
group Id
OG000
value
20
units
Participants

description

Number of days from beginning of orally administered lithium carbonate to the end of orally administered lithium carbonate

dispersion Type

Full Range

groups

description
Patients received oral lithium carbonate once or twice daily. Treatment continued for up to 8 weeks in the absence of disease progression or unacceptable toxicity.
id
OG000
title
Treated Patients

param Type

MEDIAN

reporting Status

POSTED

time Frame

Up to 6 months

title

Duration of Treatment With the Study Product

type

SECONDARY

unit Of Measure

days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice